Anti-Phospholipase A2 Receptor Autoantibodies

Monalyn De Los Reyes Labitigan, Chaim Putterman

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review


Anti-phospholipase A2 receptor (anti-PLA2R) autoantibodies were first described in 2009 and implicated in the pathogenesis of idiopathic membranous nephritis (IMN). This was a significant advance given that until then, the pathogenesis of IMN was unclear and differentiation from secondary membranous nephritis could be challenging. Since this initial study describing the anti-PLA2R antibody, several other investigators have confirmed the association of this autoantibody with IMN. Furthermore, anti-PLA2R antibodies correlate with clinical outcomes and can be used to measure response to treatment. Therefore, anti-PLA2R autoantibodies have promising applications to the diagnosis, monitoring, and treatment of IMN.

Original languageEnglish
Title of host publicationAutoantibodies
Subtitle of host publicationThird Edition
PublisherElsevier B.V.
Number of pages8
ISBN (Print)9780444563781
StatePublished - Dec 2013
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2014 Elsevier B.V. All rights reserved.


  • Anti-phospholipase A2 receptor antibodies
  • Lupus nephritis
  • Membranous nephropathy
  • Phospholipase A2 receptor
  • Podocytes
  • Systemic lupus erythematosus


Dive into the research topics of 'Anti-Phospholipase A2 Receptor Autoantibodies'. Together they form a unique fingerprint.

Cite this